1. Home
  2. Our People

James A. Brown, MD, MHA

Professor of Urology

Introduction

Development of biomarker for renal cell carcinoma metastatic potential. Prostate and renal cancer outcomes research. Development of translational biomedical engineering devices related to and benefitting urologic medical care and surgery.

Current Positions

  • Professor of Urology
  • Professor of Biomedical Engineering (BME)
  • Andersen-Hebbeln Professor of Prostate Cancer Research

Education

  • MD, Baylor College of Medicine, Houston, Texas, United States
  • BS in Engineering Science, Colorado State University, Fort Collins, Colorado, United States
  • Fellow, Thomas Jefferson University Hospital, Urologic Oncology, Philadelphia, Pennsylvania, United States
  • Fellow, Indiana University School of Medicine, Urologic Laparoscopy, Indianapolis, Indiana, United States
  • Fellow, Massachusetts General Hospital, Urologic Oncology, Boston, Massachusetts, United States
  • Resident, Mayo Graduate School of Medicine, Urology, Rochester, Minnesota, United States
  • Fellow, Henry Ford Hospital, Urologic Oncology, Detroit, Michigan, United States

Center, Program and Institute Affiliations

Licenses & Certifications

  • Diplomate, American Board of Urology

Selected Publications

  • Livorsi DJ, Packiam VT, Shi Q, Alberding SY, Carter KD, Brown JA, Mason JB, Weiss JP, Steinberg RL. A pilot intervention trial to reduce the use of post-procedural antimicrobials after common endourologic surgeries. Infect Control Hosp Epidemiol. 2024 Nov 7:1-7. doi: 10.1017/ice.2024.172. Epub ahead of print. PMID: 39506499.
  • Rolig B, Brown JA. Practical, cost-effective removal of Hem-o-lok Weck clip: a novel technique. Can J Urol. 2024 Oct;31(5):12019-12021. PMID: 39462533.
  • Marchal MA, Moose DL, Varzavand A, Jordan NE, Taylor D, Tanas MR, Brown JA, Henry MD, Stipp CS. Abl kinases can function as suppressors of tumor progression and metastasis. Front Oncol. 2023 Sep 8;13:1241056. doi: 10.3389/fonc.2023.1241056. PMID: 37746268; PMCID: PMC10514900.
  • Traxel E, Richstone L, Brown JA, Mirza M, Greene K, Thavaseelan S. Preference signaling pilot in the urology match: outcomes and perceptions. Urology. 2022 Dec;170:27-32. doi: 10.1016/j.urology.2022.08.034. Epub 2022 Sep 15. PMID: 36115432.
  • Long ME, Vitale AM, Mott SL, Tracy C, Garje R, Zakharia Y, Brown JA. Decreased testosterone recovery after androgen deprivation therapy for prostate cancer. Can J Urol. 2021 Aug;28(4):10738-10742. PMID: 34378507.
  • Boi, S. K., Orlandella, R. M., Gibson, J. T., Turbitt, W. J., Wald, G., Thomas, L., Buchta Rosean, C., Norris, K. E., Bing, M., Bertrand, L., Gross, B. P., Makkouk, A., Starenki, D., Farag, K. I., Sorge, R. E., Brown, J. A., Gordetsky, J., Yasin, H., Garje, R., Nandagopal, L., Weiner, G. J., Lubaroff, D. M., Arend, R. C., Li, P., Zakharia, Y., Yang, E., Salem, A. K., Nepple, K., Marquez-Lago, T. T. & Norian, L. A. (2020). Obesity diminishes response to PD-1-based immunotherapies in renal cancer. Journal for immunotherapy of cancer 8 (2). DOI: 10.1136/jitc-2020-000725. PMID: 33427691. PMCID: PMC7757487.
  • Yong, C., Moose, D. L., Bannick, N., Gutierrez, W. R., Vanneste, M., Svensson, R., Breheny, P., Brown, J. A., Dodd, R. D., Cohen, M. B. & Henry, M. D. (2020). Locally invasive, castrate-resistant prostate cancer in a Pten/Trp53 double knockout mouse model of prostate cancer monitored with non-invasive bioluminescent imaging. PloS one 15 (9) e0232807. DOI: 10.1371/journal.pone.0232807. PMID: 32986721. PMCID: PMC7521703.
  • Yong C, Brown JA, Takacs EB. Performing Medical Education Research in Urology: Challenges and Opportunities. Curr Urol Rep. 2020 Sep 5;21(11):45. doi: 10.1007/s11934-020-00997-w. PMID: 32889609.
  • Brown, J. A., Nepple, K. G., Norian, L. A., Gibson, J. T., Norris, K. E., Wald, G., Buchta Rosean, C. M., Thomas, L. J., Boi, S. K., Bertrand, L. A., Bing, M., Gordetsky, J. B., Deshane, J. & Li, P. (2020). Obesity induces limited changes to systemic and local immune profiles in treatment-naive human clear cell renal cell carcinoma. PloS one 15 (5) e0233795. PMID: 32469992. DOI: 10.1371/journal.pone.0233795.
  • West, J. M., Ma, D., Mott, S. L. & Brown, J. A. (2020). Cell cycle progression score has potential prognostic value for stage T1 renal cell carcinomas. Urologic oncology 38 (5) 545-552. DOI: 10.1016/j.urolonc.2019.12.025. PMID: 32081562.